Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18+
SponsorShanghai Gynecologic Oncology Group
About this trial
Optimal Timing of Surgery combined with Maintenance Therapy in the Front-line Treatment of Advanced Ovarian Cancer
Eligibility criteria
Qualifiers
Females aged ≥ 18 years.
Pathologic confirmed stage IIIC and IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal carcinoma
Low, Middle tumor burden and high tumor burden with cPCI score ≤ 12 based on pre-operative CT or PET/CT examination
Complete cytoreduction can be achieved based on CT or PET/CT examination
Disqualifiers
Non-epithelial ovarian malignancies and borderline tumors
Low grade ovarian cancer
Mucinous ovarian cancer
Complete cytoreduction cannot be achieved according to preoperative evaluation, including pulmonary and hepatic parenchymal metastases, unresectable extensive pleural metastases, multiple thoracic lymph nodes metastases, brain or bone metastases
Trial design
Treatments tested in this trial
- Primary debulking surgery
- Neoadjuvant chemotherapy
- PARP inhibitor
- Bevacizumab
Treatment groups
220 Participants
are divided into 2 treatment groupsLocations
9The First People's Hospital of Foshan Foshan China
Sun Yet-Sen University Cancer Center Guangzhou China
The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou China
Zhejiang Cancer Hospital Hangzhou China
Sponsors and collaborators
Shanghai Gynecologic Oncology Group
Lead sponsor
Fudan University
Collaborator
Source ClinicalTrials.gov